Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 13 June 2018

Indication(s)

Zerbaxa is indicated for the treatment of the following infections in adults:
- Complicated intra-abdominal infections;
- Acute pyelonephritis;
- Complicated urinary tract infections.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/003772
Orphan designation No
Date First Approved 18-09-2015
Type Medicinal product subject to medical prescription
Marketing authorisation holder Merck Sharp & Dohme Limited
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions